Chest
Original ResearchSleep MedicineLeukotriene Pathways and In Vitro Adenotonsillar Cell Proliferation in Children With Obstructive Sleep Apnea
Section snippets
Subjects
The study was approved by the University of Louisville Human Research Committee, and informed consent was obtained from the legal caregiver of each participant. Assent was also obtained from children > 7 years of age. Consecutive children who underwent tonsillectomy for OSA were identified before surgery and recruited into the study. Overnight polysomnography was performed using standard methods that have been published in detail elsewhere.19 OSA was considered to be present when the
Study Population
A total of 52 children out of 54 suitable candidates with a clinical and polysomnographic diagnosis of OSA undergoing T&A agreed to participate and completed the study. The two children who did not participate were similar in every clinical aspect to those included in the study. Of the 52 collected samples, only 49 samples could be processed because in 3 samples, trypan blue exclusion tests showed excessive cell death (> 25%), which in preliminary experiments has been shown to be associated
Discussion
The present study shows that addition of LTD4 to a dissociated mixed cell culture system of adenoids and tonsils derived from children with OSA induces increased proliferative responses and release of proinflammatory cytokines. Furthermore, treatment with LT antagonists not only markedly reduces proliferation in a dose-dependent fashion, but it also reveals striking differences in the potencies of zileuton, montelukast, and the cysLT receptor 1 and 2 antagonist, BAY u9773. Interestingly, the
References (33)
- et al.
The correlation among obesity, apnea-hypopnea index, and tonsil size in children
Chest
(2006) - et al.
Adenoid size is related to severity but not the number of episodes of obstructive apnea in children
J Pediatr
(1998) - et al.
Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome
Chest
(2006) - et al.
Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea
J Pediatr
(2001) - et al.
Differential expression of cysteinyl leukotriene receptors 1 and 2 in tonsils of children with obstructive sleep apnea syndrome or recurrent infection
Chest
(2004) - et al.
Cysteinyl leukotriene receptors are expressed by tonsillar T cells of children with obstructive sleep apnea
Chest
(2008) - et al.
Agonist and antagonist activities of the leukotriene analogue BAY u9773 in guinea pig lung parenchyma
Eur J Pharmacol
(1998) - et al.
High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea
Chest
(1997) - et al.
Snoring in preschool children: prevalence and association with nocturnal cough and asthma
Chest
(2003) - et al.
Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma
Biochem Pharmacol
(2002)
Molecular and functional aspects of human cysteinyl leukotriene receptors
Pharmacol Res
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study
Ann Allergy Asthma Immunol
Cytokines locally produced by lymphocytes removed from the hypertrophic nasopharyngeal and palatine tonsils
Int J Pediatr Otorhinolaryngol
Epidemiology of pediatric obstructive sleep apnea
Proc Am Thorac Soc
Pathophysiology of upper airway obstruction: a developmental perspective
Sleep
Pathophysiology of pediatric obstructive sleep apnea
Proc Am Thorac Soc
Cited by (0)
None of the authors have any conflict of interest to declare.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).
- 1
Dr. Gozal is supported by National Institutes of Health grants Nos. HL-065270, HL-086662, and HL-083075, the Commonwealth of Kentucky Research Challenge for Excellence Trust Fund, and the Children's Foundation Endowment for Sleep Research.
- 2
Dr. Kheirandish-Gozal is supported by an investigator-initiated grant from the Merck Company.
- 3
Dr. Bhattacharjee is supported by a fellowship from Jazz Pharmaceuticals.